Abstract
Lymphokine-activated killer (LAK) cells can be isolated as tumor-specific killer cells from a tumor-bearing host, after selective expansion in vitro by culture in interleukin 2 (IL-2). Animal experiments as well as clinical trials have shown that the adoptive transfer of these MHC unrestricted killer cells into tumor bearing hosts can cause the regression of cancer in selected patients. Here, Steven Rosenberg details his group's work on LAK cell therapy, and suggests how the clinical benefits gained so far can be improved upon.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
